Last reviewed · How we verify
Biotec Pharmacon ASA — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| SBG | SBG | phase 3 | BMP antagonist | Bone morphogenetic protein (BMP) signaling | Orthopedics / Rare Genetic Disorders | |
| Soluble beta-glucan (SBG) | Soluble beta-glucan (SBG) | phase 3 | Immunostimulant | Dectin-1, Complement Receptor 3 (CR3) | Immunology |
Therapeutic area mix
- Immunology · 1
- Orthopedics / Rare Genetic Disorders · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- RDC Clinical Pty Ltd · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Biotec Pharmacon ASA:
- Biotec Pharmacon ASA pipeline updates — RSS
- Biotec Pharmacon ASA pipeline updates — Atom
- Biotec Pharmacon ASA pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Biotec Pharmacon ASA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biotec-pharmacon-asa. Accessed 2026-06-09.